Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      REGAIN - an opportunity for people with hearing loss to take part in a clinical trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are inviting people with hearing loss to participate in a ground breaking clinical trial to test a new drug treatment for hearing loss.

      By: REGAIN | London, 13 July 2017

      Currently the only option for people with inner ear hearing loss is to wear a hearing aid, or, for those with severe to profound hearing loss, a cochlear implant. These devices help people to communicate, but do not treat the underlying cause of their hearing loss. With one in six people in the UK having hearing loss, there is an urgent need for new treatments. The researchers of the REGAIN project (REgeneration of inner ear hair cells with GAmma-secretase Inhibitors) have worked for years to develop a new drug that could regenerate inner ear (cochlear) hair cells, and they are now at the stage of testing if the drug is safe to use and if it affects the ability to hear in people.

      Testing new treatments

       

      New drugs that could potentially treat hearing loss must first be tested in clinical trials. To test a drug in people for the first time, a ‘first-in-man’, or phase I, study is conducted. The aim is to test how safe the drug is in a small group of people. Once this has been proven, the next step is to test the drug in a larger group of people, to see if the drug works and to continue monitoring its safety. This is a phase II study.

      The development of new treatments and testing in clinical trials is carefully watched over by the health regulatory authorities and requires their approval to proceed. This is in line with UK and EU law and best practice guidance that governs how clinical trials are designed and conducted.

      The REGAIN Study (REgeneration of inner ear hair cells with GAmma-secretase Inhibitors)



      In 2015, the European Union awarded a Horizon2020 research grant to a group of leading scientists and clinicians from across Europe, to develop and test a new drug with the potential to regenerate inner ear (cochlear) hair cells and improve hearing. The project is called REGAIN, and the drug is a Gamma Secretase Inhibitor (GSI). The REGAIN group has shown in animal studies that this class of drugs is able to turn on a chemical ‘switch’ to produce new hair cells from other cells in the inner ear, called ‘supporting cells’, and improve hearing of these animals. After completing the preclinical safety testing according to UK and EU regulations, the group are now at the stage of testing if the drug is safe to use in people and if it affects their ability to hear.

      First-in-Man Clinical Trial (Phase I)

      The first-in-man clinical trial will test a drug of this class in people for the first time. It is designed to assess how safe the drug is in up to 24 people with hearing loss. The study team at the UCL Ear Institute and Royal National Throat Nose and Ear Hospital (UCLH NHS Foundation Trust), led by ENT surgeons Professor Anne Schilder and Professor Shakeel Saeed, are looking for people with hearing loss who are interested in taking part in this trial.

      Who can participate?

      The team are looking for people aged 18-80 years with mild to moderate sensorineural hearing loss, who are either using or have been previously offered a hearing aid. People are eligible to take part in the study if they have had hearing loss for less than 10 years. Participants must be willing to refrain from wearing their hearing aid in the ear to be treated for three weeks, the duration of treatment.

      People who suffer from tinnitus, and consider this to be more of a problem than their hearing loss, are not eligible for the study.

      Where and when is it taking place?

      The study will start in August 2017 and take place at the Royal National Throat Nose and Ear Hospital (UCLH NHS Foundation Trust). This is the largest ear, nose and throat hospital in the UK, and hosts the European Centre for Audiological Medicine and Research. Each participant will be asked to attend the hospital for nine visits over 14 weeks; these visits include:

      • a screening visit with a range of hearing and balance tests to assess if they are eligible to take part
      • three visits, one week apart, for administration of the drug and a range of tests to assess safety of the drug (including hearing and balance tests)
      • follow up visits to continue assessing the safety of the drug.

      How is the drug administered?

      The drug will be injected through the ear drum into the middle ear, using a local anaesthetic to numb the ear drum. This technique is regularly practiced to deliver other drugs inside the ear, such as corticosteroids for the treatment of Ménière's disease.

      Participating in the REGAIN study will require considerable time and commitment over 14 weeks. The study is designed to rigorously test the safety of the drug, which means receiving the drug three times, and attending regular appointments for tests at set times.

      The results of this Phase I trial will inform the next trial stage – the Phase II trial - which will focus on how the drug affects hearing. This study will take place in the UK, and at partner sites in Greece and Germany, from the end of 2017.

      All potential participants will be provided with detailed information about the study, including the potential risks and benefits, so they can make an informed choice about whether to take part.

      More information

      If you are interested in taking part in the study, and would like to receive further information, please contact the REGAIN research team:

      By telephone: 020 3108 9344
      By email: ei-regain@ucl.ac.uk
      Or visit our website.

      To find out more information about clinical trials, please visit the UK Clinical Trials Gateway.

      Recent Posts

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard
      11 October 2018

      Scientifically speaking

      A project based at Cincinnati Children’s Hospital in the US is using virtual reality technology to assess children’s hearing. Dr Hannah Stewart tells us how.

      By: Dr Hannah Stewart
      11 October 2018

      Recent Posts

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard
      11 October 2018

      Scientifically speaking

      A project based at Cincinnati Children’s Hospital in the US is using virtual reality technology to assess children’s hearing. Dr Hannah Stewart tells us how.

      By: Dr Hannah Stewart
      11 October 2018

      More like this

      We're really proud of everyone who's a part of Action on Hearing Loss, and hope you'll feel inspired to become a part of our community.​

      We campaign for changes that make life better for people who are confronting deafness, tinnitus and hearing loss.

      Our ears are our organs of hearing and balance. They have three parts: the outer, middle and inner ear.